In recent years, due to the advancements and widespread adoption of myositis‐specific autoantibodies (MSAs) and myositis‐associated autoantibodies (MAAs), clinicians experienced a more in‐depth understanding of the diagnosis and treatment management of ASS. This evidence concerns the gene MAPKAPK5-AS1 and myositis disease.